Abstract： Objective:To investigate the effect of sindilizumab combined with thermoradiotherapy in the treatment of perimenopausal cervical cancer.Methods:Eighty-six patients with perimenopausal cervical cancer treatment in the People′s Hospital of Guangxi Zhuang Autonomous Region from July 2019 to July 2021 were perspectively selected and divided into the study group and the control group by random number table method, 43 cases in each group. The control group was given chemoradiotherapy + hyperthermia, and the study group was given chemoradiotherapy + hyperthermia + sindillizumab. The clinical benefit reaction, adverse reaction, survival rate, serum levels of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), mRNA expression levels of programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) before and after treatment were compared between the two groups.Results:The objective response rate (ORR) and disease control rate (DCR) in the study group were higher than those in the control group: 55.82%(24/43) vs. 32.56%(14/43), 69.77%(30/43) vs. 48.84%(21/43), there were statistical differences ( χ2 = 4.71, 3.90, P<0.05). After treatment, the proportion of physical strength, body weight and pain relief in the study group were higher than those in the control group: 67.44%(29/43) vs. 41.86%(18/43), 58.14%(25/43) vs. 30.23%(13/43), 67.44%(29/43) vs. 44.19%(19/43), there were statistical differences ( χ2 = 5.68, 6.79, 4.72, P<0.05). The levels of serum EGFR, HER2, PD-1 mRNA and PD-L1 mRNA in the two groups after treatment were lower than those before treatment, and the differences of EGFR, HER2, PD-1 mRNA and PD-L1 mRNA before and after treatment in the study group were greater than those in the control group: (3.62 ± 0.38) mg/L vs. (2.87 ± 0.21) mg/L, (5.85 ± 0.51) mg/L vs. (3.91 ± 0.45) mg/L, 0.55 ± 0.08 vs. 0.34 ± 0.05, 0.19 ± 0.05 vs. 0.13 ± 0.04, there were statistical differences ( P<0.05). There was no statistical difference in the incidence of toxic side effects between the two groups ( P>0.05). The 1-year survival rate between the two groups had no statistical difference ( P>0.05). Conclusions:Sindilizumab combined with thermoradiotherapy can help to modulate EGFR and HER2 in perimenopausal cervical cancer patients, and can improve the therapeutic effect with high safety.